Congenital deficiency of alpha-2-adrenoceptors on human platelets: description of two cases

Thromb Haemost. 1987 Dec 18;58(4):1012-6.

Abstract

The biochemistry and functionality of platelets from two related subjects (mother and son) with alpha-2-adrenoceptor-deficient platelets has been evaluated. Radioligand binding experiments with the specific alpha-2-adrenergic-receptor antagonist, 3H-yohimbine, showed a drastic reduction of alpha-2-adrenoceptors in platelets from both subjects in comparison with the control values. Electron microscopy studies revealed a normal morphology and a normal number of alpha granules and dense bodies. Levels of adenine nucleotides; 5-hydroxytryptamine; B-thromboglobulin; platelet-factor-4 and thromboxane A2 production were within normal limits. Platelet aggregation and 5-hydroxytryptamine production in response to adrenalin (at concentrations up to 50 microM) were absent, whereas ADP, AA, PAF, collagen and thrombin-induced aggregation, secretion, Ca++ flux and thromboxane A2 production were normal. The inhibitory effect caused by different concentrations of prostacyclin on Ca++ flux, aggregation, secretion and thromboxane A2 production of platelet functionally lacking of alpha-2-adrenoceptor was not distinguishable from control platelets and platelets preincubated with yohimbine.

Publication types

  • Case Reports
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Blood Platelet Disorders / blood
  • Blood Platelet Disorders / congenital*
  • Blood Platelet Disorders / genetics
  • Blood Platelets / drug effects
  • Blood Platelets / metabolism*
  • Calcium / blood
  • Child
  • Epinephrine / pharmacology
  • Epoprostenol / pharmacology
  • Female
  • Humans
  • In Vitro Techniques
  • Male
  • Receptors, Adrenergic, alpha / metabolism*
  • Yohimbine / pharmacology

Substances

  • Receptors, Adrenergic, alpha
  • Yohimbine
  • Epoprostenol
  • Calcium
  • Epinephrine